Acute myeloid leukemia (AML) is one of the most common types of leukemia in adults, with an average first diagnosis at age 68, and has historically carried poor prognosis due to various genetic alterations and abnormalities that complicate…
Category: biotech/medical – Page 48
Artificial Intelligence (AI) and Neuroscience are two fields, but they are closely related to each other. Artificial intelligence can provide powerful tools for neuroscience research, and its application in neurological diseases is of great importance. The convergence of AI and neuroscience has sparked a paradigm shift in our understanding of the brain and its intricate mechanisms.
Here, Creative Biolabs explores the remarkable impact of AI in neuroscience research, highlighting its potential to unlock new frontiers in our quest to unravel the mysteries of the brain.
Neuroscience research generates vast amounts of complex data, ranging from molecular and cellular information to data generated by large-scale brain activity. For researchers, analyzing and decoding this wealth of data is a major challenge. AI technology steps in to address just this problem.
Researchers have used a mind-reading brain implant to continuously play a paralyzed person’s thoughts through a speaker, allowing them to talk again.
In this episode, we welcome Prof. Dr.-Ing. Maurits Ortmanns, a leading expert in ASIC design and professor at the University of Ulm, Germany. With a distinguished career in microelectronics, Dr. Ortmanns has contributed extensively to the development of integrated circuits for biomedical applications. He shares insights into the critical role of ASIC (Application-Specific Integrated Circuit) design in advancing neurotech implants, focusing on low-power, high-speed circuits that are essential for optimizing the performance and reliability of these devices. Dr. Ortmanns also discusses the challenges and future of circuit integration in neurotechnology.
Top 3 Takeaways:
“Each ASIC is very low in cost because the development cost is spread across millions of units. The actual production cost is minimal; the primary expense lies in the development time until the first chips are produced and ready for manufacturing.” “For an inexperienced engineer, it typically takes about six months to a year to design the blueprint for the chip. Then, depending on the manufacturer, it takes an additional four to six months for the actual fabrication of the ASIC. Finally, you would need another one to two months for testing, so the total turnaround time for a small chip is approximately one and a half years.” “Let’s take the example of a neuromodulator. You need recordings or data from neurons and stimulation data going to the neurons, so you essentially have these two components. Then, you encounter challenges like stimulation artifacts. One person might focus on eliminating the stimulation artifact in the recording channel. That requires additional algorithms or hardware, and the data needs to be digitized, which is another task. You may also have someone working on a compression algorithm and building digital circuitry to compress the raw input data. Then, there’s the data interface, power management, and wireless energy delivery. Each person works on their specific innovation, and if everything is well-planned and lucky, all these pieces can come together to create a complete system. However, sometimes you simply don’t have a breakthrough idea for power management or communication.” 0:45 Do you want to introduce yourself better than I just did?
3:15 What is integrated circuit design?
7:30 What are ASIC’s? How are they used in neurotech?
10:15 How does the million dollar fab cost get split into each chip?
James Kinross, a colon cancer surgeon, believes that changes in the gut microbiome are likely contributing to rising rates of the disease in young people.
A look inside Mindstate Design Labs’ effort to design drugs that reliably produce specific states of consciousness.
Once considered obscure or opportunistic, invasive fungal infections are now surfacing with alarming frequency — and in patients and places doctors never used…
An unusual public health policy in Wales may have produced the strongest evidence yet that a vaccine can reduce the risk of dementia. In a new study led by Stanford Medicine, researchers analyzing the health records of Welsh older adults discovered that those who received the shingles vaccine were 20% less likely to develop dementia over the next seven years than those who did not receive the vaccine.
The remarkable findings, published in Nature, support an emerging theory that viruses that affect the nervous system can increase the risk of dementia. If further confirmed, the new findings suggest that a preventive intervention for dementia is already close at hand.
A revolution is underway in gene editing—and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.
A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.
He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.
Advances recognized by science’s most lucrative awards include Large Hadron Collider experiments and groundbreaking weight-loss treatments.